American biopharma company Vertex Pharmaceuticals (Nasdaq: VRTX) has announced strong third quarter 2023 financial results and raised its guidance for product revenues in 2023.
Revenues came in at $2.48 billion, a 6% increase compared from the same period of 2022, primarily driven by the strong performance of cystic fibrosis med Trikaftra (elexacaftor/tezacaftor/ivacaftor).
On a generally accepted accounting principles (GAAP) and non-GAAP basis, net income increased by 11% and 2%, respectively, to $1.04 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze